HIPK2抑制非小细胞肺癌上皮间质转化及迁移侵袭的作用及机制
Mechanical function of HIPK2 in epithelial-mesenchymal transition and metastasis of non-small cell lung cancer

DOI: 10.6040/j.issn.1671-7554.0.2016.227

Keywords: 癌,非小细胞肺,迁移,侵袭,上皮间质转化,同源结构域相互作用蛋白激酶2,
Carcinoma, non-small cell lung,Epithelial-mesenchymal transition,Homeodomain interacting protein kinase 2,Migration,Invasion

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression[J]. J Mammary Gland Biol Neoplasia, 2010, 15(2):117-134.
[2]	Kim EA, Kim JE, Sung KS, et al. Homeodomain-interacting protein kinase 2(HIPK2)targets beta-catenin for phosphorylation and proteasomal degradation[J]. Biochem Biophys Res Commun, 2010, 394(4):966-971.
[3]	Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: new biological insights and recent therapeutic advances[J]. CA Cancer J Clin, 2011, 61(2):91-112.
[4]	Shimizu H, Yamagishi S, Chiba H, et al. Methionine aminopeptidase 2 as a potential therapeutic target for human non-small-cell lung cancers[J]. Adv Clin Exp Med, 2016, 25(1):117-128.
[5]	Kim YH, Choi CY, Lee SJ, et al. Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors[J]. J Biol Chem, 1998, 273(40):25875-25879.
[6]	Trapasso F, Aqeilan RI, Iuliano R, et al. Targeted disruption of the murine homeodomain-interacting protein kinase-2 causes growth deficiency in vivo and cell cycle arrest in vitro[J]. DNA Cell Biol, 2009, 28(4):161-167.
[7]	Tanoue LT, Tanner NT, Gould MK, et al. Lung cancer screening[J]. Am J Respir Crit Care Med, 2015, 191(1):19-33.
[8]	Kokudo T, Suzuki Y, Yoshimatsu Y, et al. Snail is required for TGFbeta-induced endothelial-mesenchymal transition of embryonic stem cell-derived endothelial cells[J]. J Cell Sci, 2008, 121(Pt 20):3317-3324.
[9]	Onder TT, Gupta PB, Mani SA, et al. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways[J]. Cancer Res, 2008, 68(10):3645-3654.
[10]	Soltermann A. Epithelial-mesenchymal transition in non-small cell lung cancer[J]. Pathologe, 2012, 33 Suppl 2:311-317.
[11]	Puca R, Nardinocchi L, Givol D, et al. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells[J]. Oncogene, 2010, 29(31): 4378- 4387.
[12]	Nodale C, Sheffer M, Jacob-Hirsch J, et al. HIPK2 downregulates vimentin and inhibits breast cancer cell invasion[J]. Cancer Biol Ther, 2012, 13(4):198-205.
[13]	屈若祎, 周宝森. 2004-2010 年中国肺癌死亡分布及趋势分析[J].中国卫生统计, 2014,31(6):932-935. QU Ruoyi, ZHOU Baosen. Analysis of distribution and trend of lung cancer mortality in China between 2004-2010[J]. Chinese Journal of Health Statistics, 2014, 31(6):932-935.
[14]	Valente D, Bossi G, Moncada A, et al. HIPK2 deficiency causes chromosomal instability by cytokinesis failure and increases tumorigenicity[J]. Oncotarget, 2015, 6(12):10320-10334.
[15]	Wei G, Ku S, Ma GK, et al. HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis[J]. Proc Natl Acad Sci U S A, 2007, 104(32):13040-13045.
[16]	Puca R, Nardinocchi L, Pistritto G, et al. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells[J]. Gynecol Oncol, 2008, 109(3):403-410.
[17]	Aigner K, Dampier B, Descovich L, et al. The transcription factor ZEB1(deltaEF1)promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity[J]. Oncogene, 2007, 26(49):6979-6988.
[18]	Eger A, Aigner K, Sonderegger S, et al. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells[J]. Oncogene, 2005, 24(14):2375-2385.

Full-Text